What is the equity of Dexcom this year?
Dexcom has equity of 2.1 B USD this year.
Dexcom Equity 2025
Dexcom Equity
2.1 B USD
Ticker
DXCM
ISIN
US2521311074
WKN
A0D9T1
In 2025, Dexcom's equity was 2.1 B USD, a 1.64% increase from the 2.07 B USD equity in the previous year.
Dexcom Aktienanalyse
What does Dexcom do?
Dexcom Inc is a US medical technology company specializing in the development and manufacturing of medical devices for monitoring blood sugar levels in diabetes. The company was founded in 1999 by Scott Glenn and John Burd and is headquartered in San Diego, California. Dexcom's history began with the development of a continuous glucose sensor by Scott Glenn, who himself has Type 1 diabetes. In 2006, the company received approval from the US Food and Drug Administration (FDA) for its first continuous glucose sensor, which was marketed as the "Dexcom STS". Since then, the company has developed and launched numerous other products. Dexcom's business model is based on offering solutions to improve the quality of life for people with diabetes through the use of modern technology. The company primarily offers continuous glucose monitoring (CGM) systems, which continuously and in real-time monitor blood sugar levels to optimize insulin therapy and avoid hypoglycemia. Dexcom's goal is to make the daily management of diabetes easier and safer, and to improve the quality of life for those affected. Currently, Dexcom offers two CGM systems: the "Dexcom G6" and the "Dexcom G7". The G6 system has been on the market since 2018 and has been used by over one million people worldwide. It consists of three components: a sensor, a transmitter, and a receiver. The sensor is placed under the skin and continuously measures glucose levels in the tissue. The transmitter sends the measurements to the receiver, which displays the current blood sugar level to the patient. Another option is to connect the system to a smartphone app. The G7 system is still in development and is expected to be launched in 2021. It promises even easier handling and longer battery life. Dexcom has also formed partnerships with other companies, such as insulin pump manufacturers like Tandem Diabetes Care, to enable integration of CGM systems into these devices and enable automated insulin therapy. Currently, Dexcom employs over 3,800 people worldwide and operates in over 50 countries. The company has experienced strong growth in recent years and has steadily increased its revenues. In 2019, Dexcom's revenue was approximately $1.5 billion, representing a 43% increase from the previous year. Overall, Dexcom has established itself as a leading provider in the field of continuous glucose monitoring with its innovative products and focus on improving the quality of life for people with diabetes. The company has successfully made the daily lives of millions of individuals worldwide easier and has become an important partner in diabetes care. Dexcom ist eines der beliebtesten Unternehmen auf Eulerpool.com.Equity Details
Analyzing Dexcom's Equity
Dexcom's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Dexcom's equity is essential for assessing its financial health, stability, and value to shareholders.
Year-to-Year Comparison
Evaluating Dexcom's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.
Impact on Investments
Dexcom's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.
Interpreting Equity Fluctuations
Fluctuations in Dexcom’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.
Frequently Asked Questions about Dexcom stock
What was the equity of Dexcom compared to the previous year?
The equity of Dexcom has increased/decreased by 1.64% increased compared to the previous year.
What impact does a high equity have on investors of Dexcom?
A high equity is advantageous for investors of Dexcom as it is an indicator of the company's financial stability and its ability to manage risks and challenges.
What impact does low equity have on investors of Dexcom?
A low equity can be a risk for investors of Dexcom, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.
How does an increase in equity of Dexcom affect the company?
An increase in equity of Dexcom can strengthen the company's financial position and improve its ability to make investments in the future.
How does a reduction in the equity of Dexcom affect the company?
A reduction in equity of Dexcom can affect the financial situation of the company and lead to a higher dependence on debt capital.
What are some factors that influence the equity of Dexcom?
Some factors that can affect the equity of Dexcom include profits, dividend payments, capital increases, and acquisitions.
Why is the equity of Dexcom so important for investors?
The equity of Dexcom is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.
What strategic measures can Dexcom take to change the equity?
To change equity, Dexcom can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.
How much dividend does Dexcom pay?
Over the past 12 months, Dexcom paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Dexcom is expected to pay a dividend of 0 USD.
What is the dividend yield of Dexcom?
The current dividend yield of Dexcom is .
When does Dexcom pay dividends?
Dexcom pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Dexcom?
Dexcom paid dividends every year for the past 0 years.
What is the dividend of Dexcom?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is Dexcom located?
Dexcom is assigned to the 'Health' sector.
Wann musste ich die Aktien von Dexcom kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Dexcom from 8/2/2025 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 8/2/2025.
When did Dexcom pay the last dividend?
The last dividend was paid out on 8/2/2025.
What was the dividend of Dexcom in the year 2024?
In the year 2024, Dexcom distributed 0 USD as dividends.
In which currency does Dexcom pay out the dividend?
The dividends of Dexcom are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
The Dexcom stock can be added to a savings plan with the following providers: Trade Republic and Consorsbank
Andere Kennzahlen von Dexcom
Our stock analysis for Dexcom Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Dexcom Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
